Evidence map›Paper›PMID 35152413›Full record

ArticleActa psychiatrica Scandinavica2022

Antidepressant use during pregnancy and risk of adverse neonatal outcomes: A comprehensive investigation of previously identified associations.

Anna-Sophie Rommel, Natalie C Momen, Nina Maren Molenaar, Esben Agerbo, Veerle Bergink, Trine Munk-Olsen, Xiaoqin Liu

Abstract read
In one paragraph

Article in Acta psychiatrica Scandinavica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Maternal mental disorders and neonatal outcomes: Danish population-based cohort study.The British journal of psychiatry : the journal of mental science · 2025
    Article
  8. Article
  9. Article
  10. Frontiers in cell and developmental biology · 2023
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Anna-Sophie RommelDepartment of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York, USA.ORCID 0000-0003-4121-8631
Natalie C MomenNCRR-The National Centre for Register-based Research, Aarhus University, Aarhus, Denmark.ORCID 0000-0002-9832-8500
Nina Maren MolenaarDepartment of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Esben AgerboNCRR-The National Centre for Register-based Research, Aarhus University, Aarhus, Denmark.
Veerle BerginkDepartment of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Trine Munk-OlsenNCRR-The National Centre for Register-based Research, Aarhus University, Aarhus, Denmark.
Xiaoqin LiuNCRR-The National Centre for Register-based Research, Aarhus University, Aarhus, Denmark.

Funding

Relapse risk after Discontinuation of Antidepressants during Pregnancy (R-DAP study)R01MH122869 · NIMH · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Veerle Bergink · 2020 to 2026
$4.3M
NIMH NIH HHS R01 MH122869
6 · The paper itself

Abstract

objectivePrenatal antidepressant use is widespread. Observational studies have investigated the neonatal effects of prenatal antidepressant exposure with inconclusive results. We aimed to comprehensively investigate the associations between prenatal antidepressant exposure and the most commonly studied adverse neonatal outcomes: preterm birth, birthweight, poor neonatal adaptation, persistent pulmonary hypertension of the neonate (PPHN), neonatal admission and congenital malformations.

methodsWe included 45,590 singletons (born 1997-2015) whose mothers used antidepressants within one year before pregnancy. Children were categorised into two groups: continuation (antidepressant use before and during pregnancy) or discontinuation (antidepressant use before but not during pregnancy). We applied random-effects logistic and linear regressions, adjusting for covariates.

resultsAfter adjusting for confounders, prenatal antidepressant exposure was associated with a 2.3 day (95% CI -2.9; -2.0) decrease in gestational age and a 51 g (95% CI -62g; -41 g) decrease in birthweight. The continuation group was at increased risk for moderate-to-late preterm birth (32-37 weeks) (aOR = 1.43; 95%CI 1.33; 1.55), moderately low birthweight (1500-2499 g) (aOR = 1.28; 95%CI 1.17; 1.41), postnatal adaptation syndrome (aOR = 2.59; 95%CI 1.87; 3.59) and neonatal admission (aOR = 1.52; 95%CI 1.44; 1.60) compared to the discontinuation group.

conclusionPrenatal antidepressant exposure was associated with small decreases in gestational age and birthweight, as well as higher risk for moderate-to-late preterm birth, moderately low birthweight, neonatal admission and postnatal adaptation syndrome. No differences in risk were found for PPHN, or congenital malformations. The causality of the observed associations cannot be established due to the potential for unmeasured residual confounding linked to the underlying disease.

Indexed as

Premature BirthAntidepressive AgentsBirth WeightChildFemaleHumansInfant, NewbornMiddle AgedPregnancyPregnancy OutcomeAntidepressive Agentsantidepressantslow birthweightneonatal outcomesperinatal depressionpreterm birth

Identifiers

PMID35152413
PMCPMC9117424

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.